ArticleAnnals of translational medicine2019

An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.

Muhammad Zubair Afzal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.